Horizon Therapeutics Plc
NASDAQ:HZNP 4:00:00 PM EDT
| Market Cap (Intraday) | 22.79B |
| Current PE | 61.27 |
| Forward PE | 19.47 |
| 2yr Forward PE | 15.72 |
| 10-Day MA | $100.57 |
| 50-Day MA | $107.45 |
| 200-Day MA | $93.64 |
Horizon Therapeutics Plc Stock, NASDAQ:HZNP
70 St. Stephen's Green, 1 Burlington Road, Dublin, Dublin 4
United States of America
Phone: +353.1.772.2100
Number of Employees: 2115
Description
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.